Tyra Biosciences Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Tyra Biosciences Inc 's ROA in the second quarter of 2026?
Tyra Biosciences Inc recorded a cumulative net loss of $-149 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -43.23%.

However, within the Healthcare sector 515 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3783, from total ROA ranking in the first quarter of 2026 at 4427.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	21.14 %	21.51 %	-21.08 %	-21 %	-18.3 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-149	-131	-120	-112	-106
Return On Assets (TTM)	-43.23 %	-40.1 %	-38.85 %	-34.09 %	-30.47 %
TYRA's Total Ranking	# 3783	# 4427	# 3821	# 3786	# 3768
Total Assets (TTM) in million	383	412	283	297	317
Seq. Total Assets Change	-6.93 %	45.8 %	-4.7 %	-6.32 %	-6.64 %
Seq. Net Income Change	-	-	-	-	-

TYRA's 5 Years Annual ROA >> Back to TYRA Management Effectiveness >> Compare TYRA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 212
Sector	# 516
Overall	# 3800

Return On Assets Statistics
High	Average	Low
-3.25 %	-23.9 %	-43.07 %
(Dec 31 2021)		(Jun 30 2026)

Financial Statements
Tyra Biosciences Inc 's Assets	$ 383 million	TYRA's Balance sheet
Tyra Biosciences Inc 's Income	$ -46 million	Quarterly TYRA's Income Statement
TYRA's Income by Division		See TYRA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-21.08 %	62.56 %	-16.67 %	-13.8 %	-
Total Assets in million	283	358	220	264	307
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-120	-86	-69	-55	-26
Annual Return On Assets	-42.44 %	-24.15 %	-31.38 %	-20.93 %	-8.57 %

TYRA's 5 Years Annual ROA >> Back to TYRA Management Effectiveness >> Compare TYRA ROA to its Competitors

More Return On Assets Ratios
TYRA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
TYRA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for TYRA's Competitors
Subscribers only: Roa for Tyra Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for TYRA's Customers

You may also want to know
TYRA's Roi	TYRA's Inventory Turnover Ratio	TYRA's Growth Rates	TYRA's Dividend Comparisons
	TYRA's Profitability Ratios	TYRA's Asset Turnover Ratio	TYRA's Dividend Growth
TYRA's Roe	TYRA's Valuation Ratios	TYRA's Financial Strength Ratios	TYRA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T21:30:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.